Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT: 67Cu-SAR-BBN for GRPR-positive mCRPC
NCT05633160Phase 2Terminated
- Sponsor
- Clarity Pharmaceuticals
- Start
- Jun 2023
- Primary completion
- Apr 2025
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cu-67 SAR-Bombesin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Clarity Pharmaceuticals. Primary endpoints: Maximum tolerated dose or maximum feasible dose of a single dose of 67Cu-SAR-BBN up to 8 weeks, Recommended dose of two doses of 67Cu-SAR-BBN up to 14 weeks and 5 more. Started Jun 2023; status: terminated.
02
Drugs
Cu-67 SAR-Bombesin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05633160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633160.